InnoCare raises $160M to advance Btk inhibitor

InnoCare Pharma Ltd. (Beijing, China) said Friday that it raised $160 million in a venture round led by Loyal Valley Capital with participation from 3H Health Investment, Epiphron Capital Fund II and existing investors Vivo Capital and Shanghai Jianxin Capital.

Vivo led an untranched $55 million venture round for the Chinese cancer and autoimmune company in February 2018 (see "Global Access")...